TY - JOUR
T1 - Safety and immunogenicity of homologous versus heterologous booster dose with AZD1222, mRNA-1273, or MVC-COV1901 SARS-CoV-2 vaccines in adults
T2 - An observer-blinded, multi-center, phase 2 randomized trial
AU - Estephan, Lila
AU - Lin, Ying Chin
AU - Lin, Yi Tsung
AU - Chen, Yen Hsu
AU - Pan, Sung Ching
AU - Hsieh, Szu Min
AU - Torkehagen, Paal Fure
AU - Weng, Yi Jen
AU - Cheng, Hao Yuan
AU - Estrada, Josue Antonio
AU - Waits, Alexander
AU - Chen, Charles
AU - Lien, Chia En
N1 - Publisher Copyright:
© 2023 The Authors
PY - 2023/5/26
Y1 - 2023/5/26
N2 - Objectives: To report the safety and immunogenicity profile of a protein subunit vaccine (MVC-COV1901) compared to AZD1222 and mRNA-1273 when given as a third (booster) dose to individuals who have completed different primary vaccine regimens. Methods: Individuals were classified according to their primary vaccine regimens, including two-dose MVC-COV1901, AZD1222, or mRNA-1273. A third dose of either half-dose MVC-COV1901, full-dose MVC-COV1901, standard-dose AZD1222, half-dose mRNA-1273 was administered in a 1:1:1:1 treatment ratio to individuals with an interval range of 84–365 days after the second dose. Endpoints included safety, humoral immunogenicity, and cell-mediated immune response on trial days 15 and 29. Exploratory endpoint included testing against variants of concern (Omicron). Results: Overall, 803 participants were randomized and boosted − 201 received half-dose MVC-COV1901, 196 received full-dose MVC-COV1901, 203 received AZD1222, and 203 received half-dose mRNA-1273. Reactogenicity was mild to moderate, and less in the MVC-COV1901 booster group. Heterologous boosting provided the best immunogenic response. Boosting with mRNA-1273 in MVC-COV1901 primed individuals induced the highest antibody titers, even against Omicron, and cell-mediated immune response. Conclusions: Overall, MVC-COV1901 as a booster showed the best safety profiles. MVC-COV1901 as a primary series, with either homologous or heterologous booster, elicited the highest immunogenic response. ClinicalTrials.gov
AB - Objectives: To report the safety and immunogenicity profile of a protein subunit vaccine (MVC-COV1901) compared to AZD1222 and mRNA-1273 when given as a third (booster) dose to individuals who have completed different primary vaccine regimens. Methods: Individuals were classified according to their primary vaccine regimens, including two-dose MVC-COV1901, AZD1222, or mRNA-1273. A third dose of either half-dose MVC-COV1901, full-dose MVC-COV1901, standard-dose AZD1222, half-dose mRNA-1273 was administered in a 1:1:1:1 treatment ratio to individuals with an interval range of 84–365 days after the second dose. Endpoints included safety, humoral immunogenicity, and cell-mediated immune response on trial days 15 and 29. Exploratory endpoint included testing against variants of concern (Omicron). Results: Overall, 803 participants were randomized and boosted − 201 received half-dose MVC-COV1901, 196 received full-dose MVC-COV1901, 203 received AZD1222, and 203 received half-dose mRNA-1273. Reactogenicity was mild to moderate, and less in the MVC-COV1901 booster group. Heterologous boosting provided the best immunogenic response. Boosting with mRNA-1273 in MVC-COV1901 primed individuals induced the highest antibody titers, even against Omicron, and cell-mediated immune response. Conclusions: Overall, MVC-COV1901 as a booster showed the best safety profiles. MVC-COV1901 as a primary series, with either homologous or heterologous booster, elicited the highest immunogenic response. ClinicalTrials.gov
KW - Booster
KW - COVID-19
KW - MVC-COV1901
KW - Omicron strain
KW - SARS-CoV-2 vaccine
KW - Subunit vaccine
UR - http://www.scopus.com/inward/record.url?scp=85152906465&partnerID=8YFLogxK
U2 - 10.1016/j.vaccine.2023.04.029
DO - 10.1016/j.vaccine.2023.04.029
M3 - Article
C2 - 37080829
AN - SCOPUS:85152906465
SN - 0264-410X
VL - 41
SP - 3497
EP - 3505
JO - Vaccine
JF - Vaccine
IS - 23
ER -
